Previous 10 | Next 10 |
Celldex press release ( NASDAQ: CLDX ): Q4 GAAP EPS of -$0.56 beats by $0.03 . Revenue of $1.61M (+387.9% Y/Y) beats by $1.35M . Cash, cash equivalents and marketable securities as of December 31, 2022 were $305.0 million compared to $323.5 million as of September 30, ...
- Phase 1b multi-dose CSU data presented at AAAAI on February 26 - - Phase 2 CSU enrollment completion expected by Q3 2023 - HAMPTON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended...
Celldex Therapeutics ( NASDAQ: CLDX ) added ~12% marking the biggest intraday gain since November after the biotech announced early-stage results for its experimental monoclonal antibody barzolvolimab from patients with the skin condition urticaria. Citing data from a Phase 1b tri...
- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential best-in-class addition to a historically limited treatment landscape - - At week 12, 56% of all patients in the 1.5 mg/kg, 3.0 mg/kg and ...
Summary Nektar announced that the ISLAND study of rezpeg in lupus failed to meet its primary endpoint and that Lilly would not be advancing the drug into Phase III studies. Rezpeg continues to show concerning tolerability issues, and I expect Lilly to walk away from the program entirely...
Summary Celldex has failed too many times to inspire confidence. The company's current valuation is also quite high. However, the urticaria data is promising. We covered Celldex ( CLDX ) way back in 2017, when the company was just in between failures. Since then, i...
HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company’s Board of Directors. “We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in ...
HAMPTON, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chat at the SVB Securities Global Biopharma Conference today at 9:20 am ET. A webcast of the presentation will be available on the " Events &...
HAMPTON, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (...
- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients - - Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab-induced responses and mast cell s...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...